Met interacts with EGFR and Ron in canine osteosarcoma
| Autor: | J K, McCleese, M D, Bear, S K, Kulp, C, Mazcko, C, Khanna, C A, London |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Osteosarcoma
Hepatocyte Growth Factor Receptor Protein-Tyrosine Kinases Antineoplastic Agents Transforming Growth Factor alpha Article respiratory tract diseases ErbB Receptors Gene Expression Regulation Neoplastic Dogs Cell Line Tumor Proto-Oncogene Proteins Biomarkers Tumor Animals Humans Dog Diseases Transcriptome Signal Transduction |
| Zdroj: | Veterinary and comparative oncology. 11(2) |
| ISSN: | 1476-5829 |
| Popis: | The receptor tyrosine kinase (RTK) Met is known to be over-expressed in canine osteosarcoma (OSA). In human cancers, the RTKs Met, epidermal growth factor receptor (EGFR) and Ron are frequently co-expressed and engage in heterodimerization, altering signal transduction and promoting resistance to targeted therapeutics. We found that EGFR and Ron are expressed in canine OSA cell lines and primary tissues, EGFR and Ron are frequently phosphorylated in OSA tumour samples, and Met is co-associated with EGFR and Ron in canine OSA cell lines. Transforming growth factor alpha (TGFα) and hepatocyte growth factor (HGF) stimulation induced amplification of ERK1/2 and STAT3 phosphorylation in OSA cells and Met was phosphorylated following TGFα stimulation providing evidence for receptor cross-talk. Lastly, treatment of OSA cells with combined gefitinib and crizotinib inhibited cell proliferation in an additive manner. Together, these data support the notion that Met, EGFR and Ron interact in OSA cells and as such, may represent viable targets for therapeutic intervention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text